StemCells, Inc. announced that it has transplanted purified human neural stem cells (HuCNS-SC®) into the first five of eight patients in the final cohort of its 16-patient Phase I/II trial for dry AMD.
The trial is currently enrolling patients at five centers at:
Retina Foundation of the Southwest, Dallas, TX
Byers Eye Institute at Stanford, Stanford Hospital and Clinics, Palo Alto, CA
New York Eye and Ear Infirmary, New York, NY
Retina Foundation of the Southwest, Dallas, Texas
Retina Research Institute of Texas, Abilene, TX
The company is expecting to release the first interim results from this study in June, followed by initiation of a controlled Phase II proof-of-concept study later this year.